An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

Angela McLelland

doi:10.26182/5e97f74ea9676

An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

Angela McLelland

School of Biomedical Sciences

Research output: Thesis › Doctoral Thesis

203 Downloads (Pure)

Abstract

While L-DOPA is the gold-standard treatment for Parkinson's disease, side effects called dyskinesias can develop after long-term treatment. This thesis validated that a novel drug called UWA-101 reduces L-DOPA-induced dyskinesias in the reserpine rat model of Parkinson's disease and expanded upon this model as an inexpensive and rapid screening tool for other antidyskinetic drugs compared to more time-consuming and expensive animal models. For the first time, it was demonstrated that UWA-101 lacks the subjective effects of its parent compound MOMA ("ecstasy") and, with its antidyskinetic effects, may be an effective treatment for dyskinesias in Parkinson's disease.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	The University of Western Australia
Supervisors/Advisors	Martin-Iverson, Mathew, Supervisor Piggott, Matthew, Supervisor
Thesis sponsors	Australian Government Research Training Program
Award date	14 Feb 2020
DOIs	https://doi.org/10.26182/5e97f74ea9676
Publication status	Unpublished - 2020

Access to Document

10.26182/5e97f74ea9676

TH20 40 THESIS - DOCTOR OF PHILOSOPHY - MCLELLAND Angela Estelle - 2020
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.

Cite this

@phdthesis{79faa0761653499ea3dec352e48ed4d0,

title = "An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats",

abstract = "While L-DOPA is the gold-standard treatment for Parkinson's disease, side effects called dyskinesias can develop after long-term treatment. This thesis validated that a novel drug called UWA-101 reduces L-DOPA-induced dyskinesias in the reserpine rat model of Parkinson's disease and expanded upon this model as an inexpensive and rapid screening tool for other antidyskinetic drugs compared to more time-consuming and expensive animal models. For the first time, it was demonstrated that UWA-101 lacks the subjective effects of its parent compound MOMA ({"}ecstasy{"}) and, with its antidyskinetic effects, may be an effective treatment for dyskinesias in Parkinson's disease. ",

keywords = "Dyskinesia, Ultrasonic vocalizations, Parkinson's disease, Conditioned place prefence, Reserpine, Elevated plus maze, Rat, L-DOPA",

author = "Angela McLelland",

year = "2020",

doi = "10.26182/5e97f74ea9676",

language = "English",

school = "The University of Western Australia",

}

TY - BOOK

T1 - An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

AU - McLelland, Angela

PY - 2020

Y1 - 2020

N2 - While L-DOPA is the gold-standard treatment for Parkinson's disease, side effects called dyskinesias can develop after long-term treatment. This thesis validated that a novel drug called UWA-101 reduces L-DOPA-induced dyskinesias in the reserpine rat model of Parkinson's disease and expanded upon this model as an inexpensive and rapid screening tool for other antidyskinetic drugs compared to more time-consuming and expensive animal models. For the first time, it was demonstrated that UWA-101 lacks the subjective effects of its parent compound MOMA ("ecstasy") and, with its antidyskinetic effects, may be an effective treatment for dyskinesias in Parkinson's disease.

AB - While L-DOPA is the gold-standard treatment for Parkinson's disease, side effects called dyskinesias can develop after long-term treatment. This thesis validated that a novel drug called UWA-101 reduces L-DOPA-induced dyskinesias in the reserpine rat model of Parkinson's disease and expanded upon this model as an inexpensive and rapid screening tool for other antidyskinetic drugs compared to more time-consuming and expensive animal models. For the first time, it was demonstrated that UWA-101 lacks the subjective effects of its parent compound MOMA ("ecstasy") and, with its antidyskinetic effects, may be an effective treatment for dyskinesias in Parkinson's disease.

KW - Dyskinesia

KW - Ultrasonic vocalizations

KW - Parkinson's disease

KW - Conditioned place prefence

KW - Reserpine

KW - Elevated plus maze

KW - Rat

KW - L-DOPA

U2 - 10.26182/5e97f74ea9676

DO - 10.26182/5e97f74ea9676

M3 - Doctoral Thesis

ER -

An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

Abstract

Access to Document

Fingerprint

Cite this